Need help finding what you are looking for?
Contact Us
PUBLISHER: Lucintel | PRODUCT CODE: 1893987
PUBLISHER: Lucintel | PRODUCT CODE: 1893987
Psychedelic Drug Market Report: Trends, Forecast and Competitive Analysis to 2031
PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 3 business days
SELECT AN OPTION
The future of the global psychedelic drug market looks promising with opportunities in the hospital and mental health center markets. The global psychedelic drug market is expected to reach an estimated $5.2 billion by 2031 with a CAGR of 12.4% from 2025 to 2031. The major drivers for this market are growing societal approval of psychedelic substances, escalation in the incidence of mental health disorders, and surge in funding for the exploration and advancement of psychedelic medications.
- Lucintel forecasts that, within the application category, mental health will remain the larger segment over the forecast period due to increase in the frequency of mental illnesses like post-traumatic disorder, anxiety, and depression.
- Within the end use category, mental health center will remain the larger segment due to high use of psychedelic medications in this center to treat mental illness in mental health facilities.
- In terms of regions, North America is expected to witness highest growth over the forecast period due to rise in research and development to evaluate therapeutic effects of psychedelic drugs and presence of key players in the region.
Emerging Trends in the Psychedelic Drug Market
The psychedelic drug market is evolving rapidly with several emerging trends shaping its trajectory. These trends are affecting the market as research continues and societal attitudes change:
- Increased investment in research: Psychedelic research is being supported through substantial funding, particularly focused on mental health disorders such as depression and PTSD. This has led to a boost from venture capitalists and pharmaceutical firms, resulting in the creation of new treatments alongside clinical trials, leading to a more vibrant pipeline of psychedelic therapies.
- Regulatory changes and legalization: More jurisdictions are reconsidering their position on psychedelics, causing changes in regulations while at the same time increasing legalization for medical purposes. This trend has created a better climate for conducting clinical studies as well as providing therapeutic options within which market opportunities may be expanded.
- Expansion of clinical trials: There is an increase in the number of clinical trials involving psychedelics targeting various mental health conditions. This expansion enhances understanding of the efficacy and safety levels of psychedelic drugs, stimulating more interest and investment in this area.
- Integration into mental health care: Psychedelics have become part of mainstream mental health care practices. These approaches involve developing protocols and integrating them into existing treatment frameworks so that patients can enjoy new options that work effectively.
- Public and medical acceptance: Shifts in the perception of these drugs are also being driven by successful clinical trials and media coverage, apart from increased awareness and acceptance of psychedelics among the general public. This wider acceptance among healthcare professionals and the community is leading to an open mind on various aspects of psychedelic therapies.
Thus, these trends are changing the patterns of the psychedelic drug industry by enlarging therapeutic uses, hastening regulatory authorizations, and elevating investment. The consequence is a marketplace that becomes more dynamic, evolving swiftly with considerable growth and possibilities for creativity.
Recent Developments in the Psychedelic Drug Market
These recent developments had significant impacts on the industry's growth trajectory and direction.
- FDA Breakthrough Therapy Designations: The designation of psilocybin and MDMA by the FDA as breakthrough therapies for PTSD and depression represents major progress. Through this backing by the regulatory system, research can be expedited towards newer drugs for treating different conditions, hence contributing to the growth of the market.
- State-Level Legalization in the U.S: Other states like Oregon and Colorado have recognized medical use of psychedelics, leading to a domino effect on other areas. New opportunities are emerging from these milestones, leading to innovations in psychedelic therapies.
- Expansion of International Research: Research programs have been expanded globally, with Germany and Canada taking up that initiative, which has resulted in greater global understanding about psychedelics. Worldwide collaboration is helping produce a robust evidence base for effective psychedelic treatments.
- Emergence of Psychedelic Startups: As biotechnology continues to make strides and investment increases, several startups targeting psychedelics are mushrooming. Thus, several companies are coming up with new psychedelic compounds as well as therapeutic approaches to diversify the market.
- Growing Media and Public Interest: Market trends are being influenced by increased coverage in media concerning psychedelics as well as public interest. Positive exposure through publicity, such as celebrity endorsements, shapes public opinions and thereby demands for psychedelic therapies.
The psychedelic drug market is being revolutionized by these new trends, which have immensely improved scientific research tools, expanded treatment options, and spurred policy changes. Moreover, the market has experienced heightened dynamism with abundant growth chances on the horizon.
Strategic Growth Opportunities in the Psychedelic Drug Market
Numerous applications of psychedelic drug provide strategic growth opportunities across this market.
- Mental Health Treatments: Psychedelics can also be used to treat mental disorders such as depression, PTSD, and anxiety. This could therefore be a way through which new medicines can be developed to address these very pressing medical needs as research and clinical trials expand in this area.
- Pain Management: Moreover, studying psychedelics, particularly for chronic pain conditions, opens up avenues for therapeutic development. As such, pain management could go beyond the traditional means as researchers work towards finding more effective or less side-effect ridden ways with psychedelics as alternative treatments.
- Substance Abuse Treatment: The potential use of psychedelics in treating substance abuse disorders is under investigation. This application offers a significant growth opportunity, with the potential to develop therapies that can aid in addiction recovery and provide new solutions for a major public health issue.
- Cognitive and Behavioral Enhancements: Other uses may include cognitive enhancement or behavioral therapy when it comes to the cognitive and behavioral effects of psychedelics, not limited to mental health-related problems alone. In other words, there are potentially wider markets associated with these uses that may attract cross-sector interest.
- Integration with Digital Health Technologies: Combining psychedelic drugs with digital health technologies like virtual reality or digital therapeutics would result in an innovative approach to the treatment of patients suffering from different ailments. The integration of these technologies into psychotherapies has the capacity of making them more effective, hence opening up new markets.
These strategic growth opportunities underscore how the market for hallucinogenic drug has been changing. Stakeholders who want to take advantage of these trends and expand the business should concentrate on treatment, research, incorporation with psychiatric therapy, knowledge of regulation, and learning.
Psychedelic Drug Market Driver and Challenges
The psychedelic market is impacted by several technological, economic, and regulatory factors. An understanding of the drivers and challenges involved in this sector is paramount for success in the market.
The factors responsible for driving the psychedelic drug market include:
1. Advances in Scientific Research: The market's growth is driven by cutting-edge research into psychedelics' therapeutic potential. These include significant discoveries and clinical trials that have confirmed the efficiency of these substances in addressing mental health problems, leading to investment attraction and market growth.
2. Increasing Investment: Pharmaceutical corporations as well as venture capitalists are making forays into psychedelics, leading to accelerated market development. This funding aids research, development, and commercialization, thus causing a more vibrant and expanding market.
3. Evolving Regulatory Frameworks: Decriminalization or legalization of psychedelics such as psilocybin mushrooms in some regions has led to a favorable environment for expansion. Thus by easing regulations on these drugs allows for their use not only in research but also in clinical applications, hence increasing the overall psychedelic drug market further.
4. Growing Public and Medical Acceptance: A general increase in acceptance among both patients and doctors regarding the role of hallucinogens in treating different conditions has led to increased demand for alternative treatments. Successful clinical trials, along with positive media coverage thereof, have shifted attitudes towards psychedelics, thus supporting their respective markets.
5. Expanding Clinical Trials: There has been an upsurge in clinical trials exploring various uses of psychedelics, which have generated rich data that has propelled their growth. These enable a better understanding of what else might be done with this sort of substance; therefore, more investments will follow its path, paving the way for future developments within it.
Challenges in the psychedelic drug market are:
1. Regulatory Hurdles: One major challenge faced by companies manufacturing entertainment drugs lies in the stringent regulatory requirements as well as complicated approval procedures associated with them. Thus, navigating through these legal restrictions can be a time-consuming process riddled with high costs, thereby causing delays in entry into markets and product development.
2. Public Perception and Stigma: However, despite the increasing acceptance, there is still a lot of stigma associated with psychedelics. The popular views on such substances can influence the public's readiness to take them up for therapeutic purposes and also shape governmental policies governing the usage of these drugs.
3. Market Fragmentation: The structure of the psychedelic drug market is divided into various regions that have different policies and research standards. Such fragmentation may pose challenges to global market integration as well as complicate entrance into international markets.
Major developments within research, in addition to rising investments, have rapidly been changing the face of this industry. As such, while indicators show a potential for massive growth opportunities ahead, there are obstacles such as regulatory bottlenecks and public perception associated with them. It is therefore very important to understand these dynamics so that you can navigate through the market and ultimately exploit emerging opportunities.
List of Psychedelic Drug Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies psychedelic drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the psychedelic drug companies profiled in this report include-
- Ceruvia Lifesciences
- Braxia Scientific
- Field Trip Health
- Apex Labs
- Numinus Wellness
- Johnson & Johnson
- Psyched Wellness
- Havn Life
- Enveric Biosciences
- PharmaTher
Psychedelic Drug by Segment
The study includes a forecast for the global psychedelic drug by drug type, application, end use, and region.
Psychedelic Drug Market by Drug Type [Analysis by Value from 2019 to 2031]:
- Ketamine
- Psilocybin
- Others
Psychedelic Drug Market by Application [Analysis by Value from 2019 to 2031]:
- Mental Health
- Abuse Disorder
- Others
Psychedelic Drug Market by End Use [Analysis by Value from 2019 to 2031]:
- Hospitals
- Mental Health Center
- Others
Psychedelic Drug Market by Region [Analysis by Value from 2019 to 2031]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
Country Wise Outlook for the Psychedelic Drug Market
The psychedelic drug market is on the rise, and regulatory changes, scientific research, and shifting public opinion are shaping its progress. For example, there have been significant advancements in major markets such as the United States, China, Germany, India, and Japan that demonstrate a global interest in exploring the therapeutic potential of psychedelics.
- United States: In the US, significant steps forward have been made for the psychedelic drug market, with the FDA granting breakthrough therapy designations to psilocybin and MDMA for PTSD and depression. Different states, including Oregon and Colorado, have legalized or decriminalized psychedelics to promote more research work as well as clinical trial space.
- China: China has taken a cautious approach towards psychedelics by concentrating on research rather than legalizing their use. Nevertheless, while Chinese authorities strictly control them, there is an increasing interest in these drugs being studied for mental health issues. There are early-stage studies by Chinese institutions, but widespread adoption remains limited due to regulatory constraints.
- Germany: Germany is among the countries that have embraced psychedelics, especially when it comes to research and medical applications. Some of the latest happenings include increased funding for clinical trials and the establishment of centers specifically dedicated to studying therapeutic benefits associated with psychedelics usage. The country also seeks ways of regulating medical use, which might lead to potential future legalization.
- India: There has not been any major change in regulations or general acceptance of psychedelics within India, which still holds a conservative view on this matter. However, they are showing signs that they may be going down this route because many people are starting to consider uses for these substances in mental health. Indian researchers, together with institutions, are initiating preliminary studies while discussing how beneficial magic mushrooms can be.
- Japan: The Psychedelic drug market is at its nascent stages within Japan, characterised by limited regulatory advancement so far. This country has stringent laws regarding drugs, with psychedelics falling under the controlled substances category. Nonetheless, there is a growing academic interest in studying psychedelics, especially among some researchers who are attempting to explore their possible therapeutic applications, albeit under strict regulations.
Features of the Global Psychedelic Drug Market
- Market Size Estimates: Psychedelic drug market size estimation in terms of value ($B).
- Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
- Segmentation Analysis: Psychedelic drug market size by drug type, application, end use, and region in terms of value ($B).
- Regional Analysis: Psychedelic drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different drug types, applications, end uses, and regions for the psychedelic drug market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the psychedelic drug market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.
This report answers following 11 key questions:
- Q.1. What are some of the most promising, high-growth opportunities for the psychedelic drug market by drug type (ketamine, psilocybin, and others), application (mental health, abuse disorder, and others), end use (hospitals, mental health center, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
- Q.2. Which segments will grow at a faster pace and why?
- Q.3. Which region will grow at a faster pace and why?
- Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
- Q.5. What are the business risks and competitive threats in this market?
- Q.6. What are the emerging trends in this market and the reasons behind them?
- Q.7. What are some of the changing demands of customers in the market?
- Q.8. What are the new developments in the market? Which companies are leading these developments?
- Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
- Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
- Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
Table of Contents
1. Executive Summary
2. Market Overview
- 2.1 Background and Classifications
- 2.2 Supply Chain
3. Market Trends & Forecast Analysis
- 3.2 Industry Drivers and Challenges
- 3.3 PESTLE Analysis
- 3.4 Patent Analysis
- 3.5 Regulatory Environment
4. Global Psychedelic Drug Market by Drug Type
- 4.1 Overview
- 4.2 Attractiveness Analysis by Drug Type
- 4.3 Ketamine: Trends and Forecast (2019-2031)
- 4.4 Psilocybin: Trends and Forecast (2019-2031)
- 4.5 Others: Trends and Forecast (2019-2031)
5. Global Psychedelic Drug Market by Application
- 5.1 Overview
- 5.2 Attractiveness Analysis by Application
- 5.3 Mental Health: Trends and Forecast (2019-2031)
- 5.4 Abuse Disorder: Trends and Forecast (2019-2031)
- 5.5 Others: Trends and Forecast (2019-2031)
6. Global Psychedelic Drug Market by End Use
- 6.1 Overview
- 6.2 Attractiveness Analysis by End Use
- 6.3 Hospitals: Trends and Forecast (2019-2031)
- 6.4 Mental Health Center: Trends and Forecast (2019-2031)
- 6.5 Others: Trends and Forecast (2019-2031)
7. Regional Analysis
- 7.1 Overview
- 7.2 Global Psychedelic Drug Market by Region
8. North American Psychedelic Drug Market
- 8.1 Overview
- 8.2 North American Psychedelic Drug Market by Application
- 8.3 North American Psychedelic Drug Market by End Use
- 8.4 United States Psychedelic Drug Market
- 8.5 Mexican Psychedelic Drug Market
- 8.6 Canadian Psychedelic Drug Market
9. European Psychedelic Drug Market
- 9.1 Overview
- 9.2 European Psychedelic Drug Market by Application
- 9.3 European Psychedelic Drug Market by End Use
- 9.4 German Psychedelic Drug Market
- 9.5 French Psychedelic Drug Market
- 9.6 Spanish Psychedelic Drug Market
- 9.7 Italian Psychedelic Drug Market
- 9.8 United Kingdom Psychedelic Drug Market
10. APAC Psychedelic Drug Market
- 10.1 Overview
- 10.2 APAC Psychedelic Drug Market by Application
- 10.3 APAC Psychedelic Drug Market by End Use
- 10.4 Japanese Psychedelic Drug Market
- 10.5 Indian Psychedelic Drug Market
- 10.6 Chinese Psychedelic Drug Market
- 10.7 South Korean Psychedelic Drug Market
- 10.8 Indonesian Psychedelic Drug Market
11. ROW Psychedelic Drug Market
- 11.1 Overview
- 11.2 ROW Psychedelic Drug Market by Application
- 11.3 ROW Psychedelic Drug Market by End Use
- 11.4 Middle Eastern Psychedelic Drug Market
- 11.5 South American Psychedelic Drug Market
- 11.6 African Psychedelic Drug Market
12. Competitor Analysis
- 12.1 Product Portfolio Analysis
- 12.2 Operational Integration
- 12.3 Porter's Five Forces Analysis
- Competitive Rivalry
- Bargaining Power of Buyers
- Bargaining Power of Suppliers
- Threat of Substitutes
- Threat of New Entrants
- 12.4 Market Share Analysis
13. Opportunities & Strategic Analysis
- 13.1 Value Chain Analysis
- 13.2 Growth Opportunity Analysis
- 13.2.1 Growth Opportunities by Drug Type
- 13.2.2 Growth Opportunities by Application
- 13.2.3 Growth Opportunities by End Use
- 13.3 Emerging Trends in the Global Psychedelic Drug Market
- 13.4 Strategic Analysis
- 13.4.1 New Product Development
- 13.4.2 Certification and Licensing
- 13.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures
14. Company Profiles of the Leading Players Across the Value Chain
- 14.1 Competitive Analysis
- 14.2 Ceruvia Lifesciences
- Company Overview
- Psychedelic Drug Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
- 14.3 Braxia Scientific
- Company Overview
- Psychedelic Drug Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
- 14.4 Field Trip Health
- Company Overview
- Psychedelic Drug Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
- 14.5 Apex Labs
- Company Overview
- Psychedelic Drug Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
- 14.6 Numinus Wellness
- Company Overview
- Psychedelic Drug Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
- 14.7 Johnson & Johnson
- Company Overview
- Psychedelic Drug Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
- 14.8 Psyched Wellness
- Company Overview
- Psychedelic Drug Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
- 14.9 Havn Life
- Company Overview
- Psychedelic Drug Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
- 14.10 Enveric Biosciences
- Company Overview
- Psychedelic Drug Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
- 14.11 PharmaTher
- Company Overview
- Psychedelic Drug Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
15. Appendix
- 15.1 List of Figures
- 15.2 List of Tables
- 15.3 Research Methodology
- 15.4 Disclaimer
- 15.5 Copyright
- 15.6 Abbreviations and Technical Units
- 15.7 About Us
- 15.8 Contact Us
List of Figures
- Figure 1.1: Trends and Forecast for the Global Psychedelic Drug Market
- Figure 2.1: Usage of Psychedelic Drug Market
- Figure 2.2: Classification of the Global Psychedelic Drug Market
- Figure 2.3: Supply Chain of the Global Psychedelic Drug Market
- Figure 3.1: Driver and Challenges of the Psychedelic Drug Market
- Figure 3.2: PESTLE Analysis
- Figure 3.3: Patent Analysis
- Figure 3.4: Regulatory Environment
- Figure 4.1: Global Psychedelic Drug Market by Drug Type in 2019, 2024, and 2031
- Figure 4.2: Trends of the Global Psychedelic Drug Market ($B) by Drug Type
- Figure 4.3: Forecast for the Global Psychedelic Drug Market ($B) by Drug Type
- Figure 4.4: Trends and Forecast for Ketamine in the Global Psychedelic Drug Market (2019-2031)
- Figure 4.5: Trends and Forecast for Psilocybin in the Global Psychedelic Drug Market (2019-2031)
- Figure 4.6: Trends and Forecast for Others in the Global Psychedelic Drug Market (2019-2031)
- Figure 5.1: Global Psychedelic Drug Market by Application in 2019, 2024, and 2031
- Figure 5.2: Trends of the Global Psychedelic Drug Market ($B) by Application
- Figure 5.3: Forecast for the Global Psychedelic Drug Market ($B) by Application
- Figure 5.4: Trends and Forecast for Mental Health in the Global Psychedelic Drug Market (2019-2031)
- Figure 5.5: Trends and Forecast for Abuse Disorder in the Global Psychedelic Drug Market (2019-2031)
- Figure 5.6: Trends and Forecast for Others in the Global Psychedelic Drug Market (2019-2031)
- Figure 6.1: Global Psychedelic Drug Market by End Use in 2019, 2024, and 2031
- Figure 6.2: Trends of the Global Psychedelic Drug Market ($B) by End Use
- Figure 6.3: Forecast for the Global Psychedelic Drug Market ($B) by End Use
- Figure 6.4: Trends and Forecast for Hospitals in the Global Psychedelic Drug Market (2019-2031)
- Figure 6.5: Trends and Forecast for Mental Health Center in the Global Psychedelic Drug Market (2019-2031)
- Figure 6.6: Trends and Forecast for Others in the Global Psychedelic Drug Market (2019-2031)
- Figure 7.1: Trends of the Global Psychedelic Drug Market ($B) by Region (2019-2024)
- Figure 7.2: Forecast for the Global Psychedelic Drug Market ($B) by Region (2025-2031)
- Figure 8.1: North American Psychedelic Drug Market by Application in 2019, 2024, and 2031
- Figure 8.2: Trends of the North American Psychedelic Drug Market ($B) by Application (2019-2024)
- Figure 8.3: Forecast for the North American Psychedelic Drug Market ($B) by Application (2025-2031)
- Figure 8.4: North American Psychedelic Drug Market by End Use in 2019, 2024, and 2031
- Figure 8.5: Trends of the North American Psychedelic Drug Market ($B) by End Use (2019-2024)
- Figure 8.6: Forecast for the North American Psychedelic Drug Market ($B) by End Use (2025-2031)
- Figure 8.7: Trends and Forecast for the United States Psychedelic Drug Market ($B) (2019-2031)
- Figure 8.8: Trends and Forecast for the Mexican Psychedelic Drug Market ($B) (2019-2031)
- Figure 8.9: Trends and Forecast for the Canadian Psychedelic Drug Market ($B) (2019-2031)
- Figure 9.1: European Psychedelic Drug Market by Application in 2019, 2024, and 2031
- Figure 9.2: Trends of the European Psychedelic Drug Market ($B) by Application (2019-2024)
- Figure 9.3: Forecast for the European Psychedelic Drug Market ($B) by Application (2025-2031)
- Figure 9.4: European Psychedelic Drug Market by End Use in 2019, 2024, and 2031
- Figure 9.5: Trends of the European Psychedelic Drug Market ($B) by End Use (2019-2024)
- Figure 9.6: Forecast for the European Psychedelic Drug Market ($B) by End Use (2025-2031)
- Figure 9.7: Trends and Forecast for the German Psychedelic Drug Market ($B) (2019-2031)
- Figure 9.8: Trends and Forecast for the French Psychedelic Drug Market ($B) (2019-2031)
- Figure 9.9: Trends and Forecast for the Spanish Psychedelic Drug Market ($B) (2019-2031)
- Figure 9.10: Trends and Forecast for the Italian Psychedelic Drug Market ($B) (2019-2031)
- Figure 9.11: Trends and Forecast for the United Kingdom Psychedelic Drug Market ($B) (2019-2031)
- Figure 10.1: APAC Psychedelic Drug Market by Application in 2019, 2024, and 2031
- Figure 10.2: Trends of the APAC Psychedelic Drug Market ($B) by Application (2019-2024)
- Figure 10.3: Forecast for the APAC Psychedelic Drug Market ($B) by Application (2025-2031)
- Figure 10.4: APAC Psychedelic Drug Market by End Use in 2019, 2024, and 2031
- Figure 10.5: Trends of the APAC Psychedelic Drug Market ($B) by End Use (2019-2024)
- Figure 10.6: Forecast for the APAC Psychedelic Drug Market ($B) by End Use (2025-2031)
- Figure 10.7: Trends and Forecast for the Japanese Psychedelic Drug Market ($B) (2019-2031)
- Figure 10.8: Trends and Forecast for the Indian Psychedelic Drug Market ($B) (2019-2031)
- Figure 10.9: Trends and Forecast for the Chinese Psychedelic Drug Market ($B) (2019-2031)
- Figure 10.10: Trends and Forecast for the South Korean Psychedelic Drug Market ($B) (2019-2031)
- Figure 10.11: Trends and Forecast for the Indonesian Psychedelic Drug Market ($B) (2019-2031)
- Figure 11.1: ROW Psychedelic Drug Market by Application in 2019, 2024, and 2031
- Figure 11.2: Trends of the ROW Psychedelic Drug Market ($B) by Application (2019-2024)
- Figure 11.3: Forecast for the ROW Psychedelic Drug Market ($B) by Application (2025-2031)
- Figure 11.4: ROW Psychedelic Drug Market by End Use in 2019, 2024, and 2031
- Figure 11.5: Trends of the ROW Psychedelic Drug Market ($B) by End Use (2019-2024)
- Figure 11.6: Forecast for the ROW Psychedelic Drug Market ($B) by End Use (2025-2031)
- Figure 11.7: Trends and Forecast for the Middle Eastern Psychedelic Drug Market ($B) (2019-2031)
- Figure 11.8: Trends and Forecast for the South American Psychedelic Drug Market ($B) (2019-2031)
- Figure 11.9: Trends and Forecast for the African Psychedelic Drug Market ($B) (2019-2031)
- Figure 12.1: Porter's Five Forces Analysis of the Global Psychedelic Drug Market
- Figure 12.2: Market Share (%) of Top Players in the Global Psychedelic Drug Market (2024)
- Figure 13.1: Growth Opportunities for the Global Psychedelic Drug Market by Drug Type
- Figure 13.2: Growth Opportunities for the Global Psychedelic Drug Market by Application
- Figure 13.3: Growth Opportunities for the Global Psychedelic Drug Market by End Use
- Figure 13.4: Growth Opportunities for the Global Psychedelic Drug Market by Region
- Figure 13.5: Emerging Trends in the Global Psychedelic Drug Market
List of Tables
- Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Psychedelic Drug Market by Drug Type, Application, and End Use
- Table 1.2: Attractiveness Analysis for the Psychedelic Drug Market by Region
- Table 1.3: Global Psychedelic Drug Market Parameters and Attributes
- Table 3.1: Trends of the Global Psychedelic Drug Market (2019-2024)
- Table 3.2: Forecast for the Global Psychedelic Drug Market (2025-2031)
- Table 4.1: Attractiveness Analysis for the Global Psychedelic Drug Market by Drug Type
- Table 4.2: Market Size and CAGR of Various Drug Type in the Global Psychedelic Drug Market (2019-2024)
- Table 4.3: Market Size and CAGR of Various Drug Type in the Global Psychedelic Drug Market (2025-2031)
- Table 4.4: Trends of Ketamine in the Global Psychedelic Drug Market (2019-2024)
- Table 4.5: Forecast for Ketamine in the Global Psychedelic Drug Market (2025-2031)
- Table 4.6: Trends of Psilocybin in the Global Psychedelic Drug Market (2019-2024)
- Table 4.7: Forecast for Psilocybin in the Global Psychedelic Drug Market (2025-2031)
- Table 4.8: Trends of Others in the Global Psychedelic Drug Market (2019-2024)
- Table 4.9: Forecast for Others in the Global Psychedelic Drug Market (2025-2031)
- Table 5.1: Attractiveness Analysis for the Global Psychedelic Drug Market by Application
- Table 5.2: Market Size and CAGR of Various Application in the Global Psychedelic Drug Market (2019-2024)
- Table 5.3: Market Size and CAGR of Various Application in the Global Psychedelic Drug Market (2025-2031)
- Table 5.4: Trends of Mental Health in the Global Psychedelic Drug Market (2019-2024)
- Table 5.5: Forecast for Mental Health in the Global Psychedelic Drug Market (2025-2031)
- Table 5.6: Trends of Abuse Disorder in the Global Psychedelic Drug Market (2019-2024)
- Table 5.7: Forecast for Abuse Disorder in the Global Psychedelic Drug Market (2025-2031)
- Table 5.8: Trends of Others in the Global Psychedelic Drug Market (2019-2024)
- Table 5.9: Forecast for Others in the Global Psychedelic Drug Market (2025-2031)
- Table 6.1: Attractiveness Analysis for the Global Psychedelic Drug Market by End Use
- Table 6.2: Market Size and CAGR of Various End Use in the Global Psychedelic Drug Market (2019-2024)
- Table 6.3: Market Size and CAGR of Various End Use in the Global Psychedelic Drug Market (2025-2031)
- Table 6.4: Trends of Hospitals in the Global Psychedelic Drug Market (2019-2024)
- Table 6.5: Forecast for Hospitals in the Global Psychedelic Drug Market (2025-2031)
- Table 6.6: Trends of Mental Health Center in the Global Psychedelic Drug Market (2019-2024)
- Table 6.7: Forecast for Mental Health Center in the Global Psychedelic Drug Market (2025-2031)
- Table 6.8: Trends of Others in the Global Psychedelic Drug Market (2019-2024)
- Table 6.9: Forecast for Others in the Global Psychedelic Drug Market (2025-2031)
- Table 7.1: Market Size and CAGR of Various Regions in the Global Psychedelic Drug Market (2019-2024)
- Table 7.2: Market Size and CAGR of Various Regions in the Global Psychedelic Drug Market (2025-2031)
- Table 8.1: Trends of the North American Psychedelic Drug Market (2019-2024)
- Table 8.2: Forecast for the North American Psychedelic Drug Market (2025-2031)
- Table 8.3: Market Size and CAGR of Various Application in the North American Psychedelic Drug Market (2019-2024)
- Table 8.4: Market Size and CAGR of Various Application in the North American Psychedelic Drug Market (2025-2031)
- Table 8.5: Market Size and CAGR of Various End Use in the North American Psychedelic Drug Market (2019-2024)
- Table 8.6: Market Size and CAGR of Various End Use in the North American Psychedelic Drug Market (2025-2031)
- Table 8.7: Trends and Forecast for the United States Psychedelic Drug Market (2019-2031)
- Table 8.8: Trends and Forecast for the Mexican Psychedelic Drug Market (2019-2031)
- Table 8.9: Trends and Forecast for the Canadian Psychedelic Drug Market (2019-2031)
- Table 9.1: Trends of the European Psychedelic Drug Market (2019-2024)
- Table 9.2: Forecast for the European Psychedelic Drug Market (2025-2031)
- Table 9.3: Market Size and CAGR of Various Application in the European Psychedelic Drug Market (2019-2024)
- Table 9.4: Market Size and CAGR of Various Application in the European Psychedelic Drug Market (2025-2031)
- Table 9.5: Market Size and CAGR of Various End Use in the European Psychedelic Drug Market (2019-2024)
- Table 9.6: Market Size and CAGR of Various End Use in the European Psychedelic Drug Market (2025-2031)
- Table 9.7: Trends and Forecast for the German Psychedelic Drug Market (2019-2031)
- Table 9.8: Trends and Forecast for the French Psychedelic Drug Market (2019-2031)
- Table 9.9: Trends and Forecast for the Spanish Psychedelic Drug Market (2019-2031)
- Table 9.10: Trends and Forecast for the Italian Psychedelic Drug Market (2019-2031)
- Table 9.11: Trends and Forecast for the United Kingdom Psychedelic Drug Market (2019-2031)
- Table 10.1: Trends of the APAC Psychedelic Drug Market (2019-2024)
- Table 10.2: Forecast for the APAC Psychedelic Drug Market (2025-2031)
- Table 10.3: Market Size and CAGR of Various Application in the APAC Psychedelic Drug Market (2019-2024)
- Table 10.4: Market Size and CAGR of Various Application in the APAC Psychedelic Drug Market (2025-2031)
- Table 10.5: Market Size and CAGR of Various End Use in the APAC Psychedelic Drug Market (2019-2024)
- Table 10.6: Market Size and CAGR of Various End Use in the APAC Psychedelic Drug Market (2025-2031)
- Table 10.7: Trends and Forecast for the Japanese Psychedelic Drug Market (2019-2031)
- Table 10.8: Trends and Forecast for the Indian Psychedelic Drug Market (2019-2031)
- Table 10.9: Trends and Forecast for the Chinese Psychedelic Drug Market (2019-2031)
- Table 10.10: Trends and Forecast for the South Korean Psychedelic Drug Market (2019-2031)
- Table 10.11: Trends and Forecast for the Indonesian Psychedelic Drug Market (2019-2031)
- Table 11.1: Trends of the ROW Psychedelic Drug Market (2019-2024)
- Table 11.2: Forecast for the ROW Psychedelic Drug Market (2025-2031)
- Table 11.3: Market Size and CAGR of Various Application in the ROW Psychedelic Drug Market (2019-2024)
- Table 11.4: Market Size and CAGR of Various Application in the ROW Psychedelic Drug Market (2025-2031)
- Table 11.5: Market Size and CAGR of Various End Use in the ROW Psychedelic Drug Market (2019-2024)
- Table 11.6: Market Size and CAGR of Various End Use in the ROW Psychedelic Drug Market (2025-2031)
- Table 11.7: Trends and Forecast for the Middle Eastern Psychedelic Drug Market (2019-2031)
- Table 11.8: Trends and Forecast for the South American Psychedelic Drug Market (2019-2031)
- Table 11.9: Trends and Forecast for the African Psychedelic Drug Market (2019-2031)
- Table 12.1: Product Mapping of Psychedelic Drug Suppliers Based on Segments
- Table 12.2: Operational Integration of Psychedelic Drug Manufacturers
- Table 12.3: Rankings of Suppliers Based on Psychedelic Drug Revenue
- Table 13.1: New Product Launches by Major Psychedelic Drug Producers (2019-2024)
- Table 13.2: Certification Acquired by Major Competitor in the Global Psychedelic Drug Market
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.